Effectiveness of Pre-emptive Analgesia in Children With Molar-incisor Hypomineralization (MIH)

University of Sao Paulo

Status and phase: Unknown; Early Phase 1

Conditions: Anxiety; Pain

Treatments: Drug: Ibuprofen; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT03953729

AnalgesiaMIH

Details and patient eligibility

About

Pain is defined by IASP (International Association for the Study of Pain) as "an unpleasant sensory and emotional experience associated with the damage actual or potential tissue or described in terms that suggest such harm". Episodes of pain and discomfort experienced by children are one of the main factors for fear and anxiety in dentistry, especially those that present the condition of Molar-Incisive Hipomineralization, where we observed increased levels of anxiety in relation to the treatment. In order to improve the painful sensation that patients with Molar-Incisor Hipomineralization present as well as anxiety demonstrated by these patients in face of dental treatment, the objective of present study will be to evaluate the occurrence and degree of pain after procedures dentists with administration of pre-emptive analgesia or placebo, in children with Molar-Incisive Hipomineralization. Fifty patients will be selected in the Pediatric Dentistry courses of the FORP-USP undergraduate course, aged 6 to 12 years, of both sexes, who present at least 2 (two) upper and / or lower molars affected by Molar- Incisors that need some kind of restorative treatment, extraction or endodontic treatment. Also, these patients should present enamel and dentin fractures caused by MIH, atypical restoration and / or atypical caries, and that present pain above the moderate degree (6>), after stimulation with air/water jet for 5 seconds.

Enrollment: 50 estimated patients

Sex: All

Ages: 6 to 12 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• present at least 2 (two) upper molars and/or lower affected by Molar-Incisor Hypomineralization
• restorative treatment
• extraction
• endodontic treatment
• pain above the moderate degree (6>)

Exclusion criteria

• patients with suspected of analgesics of any type or presence of acute pain in the last 24 hours before the procedure
• patient with history of hepatopathy
• bleeding hemorrhagic disorders
• hypersensitivity to components
• patients and family members who do not have a telephone or that the children will not under parental supervision in the first 24 hours after care.

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

50 participants in 2 patient groups, including a placebo group

Group 1:Ibuprofeno

Experimental group

Description:

The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the drug shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale "Children's Fear Survey Schedule-Dental Subscale" (Barberio, 2017). After 30 minutes of drug administration, treatment will start.

Treatment:

Drug: Ibuprofen

Group 2: Placebo

Placebo Comparator group

Description:

The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the placebo shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale "Children's Fear Survey Schedule-Dental Subscale" (Barberio, 2017). After 30 minutes of drug administration, treatment will start.

Treatment:

Drug: Placebo